- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
- Interventions
- Orbital Atherectomy, Balloon
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,005 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 17,105
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Bevacizumab, Carboplatin, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 503
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 332 more
- Conditions
- X-linked Hypophosphatemia, Hypophosphatemic Rickets
- Interventions
- No intervention
- Other
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 782 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2032
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
- Conditions
- Multiple Myeloma
- Interventions
- MyHOPE™ for Multiple Myeloma, MyHope HCP Portal
- Device
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 27 more
- Conditions
- TOBACCO USE CESSATION
- Interventions
- Standard Patch Treatment, 24-weeks of nicotine patch
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 568 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Major Depressive Disorder
- Interventions
- agomelatine, placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 644 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Nicole Hamblett
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 987 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Anti-Retroviral Treatment and Access to Services (ARTAS)
- Other
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,893 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Influenza
- Interventions
- GSK Bio's influenza vaccine GSK2186877A, Fluarix TM
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 43,695 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 63
- States / cities
- Alabaster, Alabama • Huntsville, Alabama • Mobile, Alabama + 51 more
- Conditions
- Loneliness, Social Isolation
- Interventions
- Need to Be Needed Intervention, Active Control Group
- Behavioral · Other
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Diolamine, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more
- Conditions
- Obstructive Sleep Apnea, Snoring
- Interventions
- Adenotonsillectomy (AT) - removal of adenoids and tonsils, Watchful Waiting
- Procedure · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 5 Years to 9 Years
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
- Conditions
- Atopic Dermatitis
- Interventions
- FB825, Placebo
- Biological · Other
- Lead sponsor
- Oneness Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 18
- States / cities
- Beverly Hills, California • Encino, California • Huntington Beach, California + 13 more
- Conditions
- Peripheral Neuropathy
- Interventions
- L-glutamine
- Dietary Supplement
- Lead sponsor
- Eastern Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Extended-release Guanfacine Hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 27
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
- Conditions
- Pancreatic Cancer
- Interventions
- Ruxolitinib, Placebo, Capecitabine
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 153
- States / cities
- Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 150 more
- Conditions
- Breast Carcinoma, Endometrial Carcinoma, Prostate Carcinosarcoma
- Interventions
- Dietary Intervention, Counseling, Therapeutic
- Dietary Supplement · Other · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- Adavosertib, Radiation Therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Interstitial Lung Diseases
- Interventions
- Nerandomilast, Placebo matching nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 25 more
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases
- Interventions
- Neuromodulation
- Device
- Lead sponsor
- Boomerang Medical
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Folsom, California • Los Angeles, California • Newport Beach, California + 16 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- INS018_055, Placebo
- Drug
- Lead sponsor
- InSilico Medicine Hong Kong Limited
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- TissueGene-C, Normal Saline
- Biological · Drug
- Lead sponsor
- Kolon TissueGene, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more
- Conditions
- Sleep Disorders
- Interventions
- Circadin 2/5/10 mg, Placebo
- Drug
- Lead sponsor
- Neurim Pharmaceuticals Ltd.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Miami Lakes, Florida • Orange City, Florida + 14 more
- Conditions
- MItochondrial Myopathies
- Interventions
- Omaveloxolone capsules, 2.5 mg, omaveloxolone capsules, 5 mg, omaveloxolone capsules, 10 mg, Placebo capsules, omaveloxolone capsules, 20 mg, omaveloxolone capsules, 40 mg, omaveloxolone capsules, 80 mg, omaveloxolone capsules, 160 mg
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Boston, Massachusetts • Akron, Ohio + 4 more